Continuing Access To The Tyrosine Kinase Inhibitor Of VEGFR 2, AG-013736 (A406) For Patients Previously Receiving AG-013736 In Clinical Trials
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 29 Jul 2017
At a glance
- Drugs Axitinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Expanded access
- Sponsors Pfizer
- 27 Feb 2017 Planned number of patients changed from 53 to 10.
- 12 Aug 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
- 01 May 2016 Status changed from recruiting to active, no longer recruiting.